These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32624333)

  • 1. Fracture risk in patients with type 2 diabetes aged ≥50 years related to HbA1c, acute complications, BMI and SGLT2i-use in the DPV registry.
    Eckert AJ; Mader JK; Altmeier M; Mühldorfer S; Gillessen A; Dallmeier D; Shah VN; Heyer C; Hartmann B; Holl RW
    J Diabetes Complications; 2020 Oct; 34(10):107664. PubMed ID: 32624333
    [No Abstract]   [Full Text] [Related]  

  • 2. Distinct trajectories of HbA
    Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
    Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).
    Brunton S; Rozjabek HM; Pilon D; Lafeuille MH; Kamstra R; Wynant W; Bookhart BK; Lefebvre P
    Curr Med Res Opin; 2019 Sep; 35(9):1607-1614. PubMed ID: 30964362
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
    Lee RH; Sloane R; Pieper C; Lyles KW; Adler RA; Van Houtven C; LaFleur J; Colón-Emeric C
    J Bone Miner Res; 2019 Nov; 34(11):2045-2051. PubMed ID: 31269274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes.
    Sawada K; Karashima S; Kometani M; Oka R; Takeda Y; Sawamura T; Fujimoto A; Demura M; Wakayama A; Usukura M; Yagi K; Takeda Y; Yoneda T
    Endocr J; 2018 Apr; 65(4):461-467. PubMed ID: 29459554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):843-849. PubMed ID: 34276009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
    Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
    Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database study.
    Lautsch D; Iglay K; Yang L; Bansal N; Markan R; Kathe N; Rajpathak S
    Curr Med Res Opin; 2020 Oct; 36(10):1583-1589. PubMed ID: 32866052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
    Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
    J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study.
    Gamaza-Chulián S; Díaz-Retamino E; González-Testón F; Gaitero JC; Castillo MJ; Alfaro R; Rodríguez E; González-Caballero E; Martín-Santana A
    BMC Cardiovasc Disord; 2021 Sep; 21(1):456. PubMed ID: 34548011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.
    Jacob S; Krentz AJ; Deanfield J; Rydén L
    Drugs; 2021 Aug; 81(12):1373-1379. PubMed ID: 34302636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control and fracture risk in elderly patients with diabetes.
    Conway BN; Long DM; Figaro MK; May ME
    Diabetes Res Clin Pract; 2016 May; 115():47-53. PubMed ID: 27242122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial.
    Bae J; Huh JH; Lee M; Lee YH; Lee BW
    Diabetes Obes Metab; 2021 Feb; 23(2):609-618. PubMed ID: 33217092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
    Goldenberg RM
    Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study.
    Li CI; Liu CS; Lin WY; Meng NH; Chen CC; Yang SY; Chen HJ; Lin CC; Li TC
    J Bone Miner Res; 2015 Jul; 30(7):1338-46. PubMed ID: 25598134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.